Sanofi (SNY) to Announce Quarterly Earnings on Thursday

Sanofi (NASDAQ:SNY) is expected to be posting its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect Sanofi to announce earnings of $1.09 per share and revenue of $12.3939 billion for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, July 30, 2026 at 7:00 AM ET.

Sanofi Stock Performance

SNY stock opened at $45.54 on Wednesday. The stock’s 50 day simple moving average is $43.49 and its 200 day simple moving average is $45.29. Sanofi has a 12-month low of $40.89 and a 12-month high of $52.68. The firm has a market cap of $110.41 billion, a P/E ratio of 12.72, a P/E/G ratio of 1.12 and a beta of 0.34. The company has a current ratio of 1.01, a quick ratio of 0.22 and a debt-to-equity ratio of 0.17.

Analyst Upgrades and Downgrades

SNY has been the subject of several recent research reports. Argus upgraded shares of Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. Morgan Stanley set a $49.00 price target on shares of Sanofi in a research report on Wednesday, July 8th. Wall Street Zen lowered shares of Sanofi from a “buy” rating to a “hold” rating in a report on Saturday, July 18th. Citigroup reaffirmed a “neutral” rating on shares of Sanofi in a research report on Monday, April 13th. Finally, BNP Paribas Exane lowered shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat.com, Sanofi has a consensus rating of “Hold” and an average price target of $49.50.

Institutional Investors Weigh In On Sanofi

A number of hedge funds have recently added to or reduced their stakes in SNY. Raymond James Financial Inc. lifted its position in Sanofi by 81.3% in the second quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock worth $284,058,000 after purchasing an additional 2,635,867 shares during the period. Morgan Stanley boosted its stake in Sanofi by 20.4% during the 4th quarter. Morgan Stanley now owns 9,102,196 shares of the company’s stock valued at $441,093,000 after purchasing an additional 1,540,271 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of Sanofi by 422.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,062,809 shares of the company’s stock valued at $50,165,000 after purchasing an additional 859,246 shares during the period. Van ECK Associates Corp increased its position in shares of Sanofi by 102.8% during the 4th quarter. Van ECK Associates Corp now owns 1,244,997 shares of the company’s stock valued at $60,333,000 after purchasing an additional 631,180 shares during the period. Finally, Armistice Capital LLC bought a new stake in shares of Sanofi in the 3rd quarter worth $28,886,000. 14.03% of the stock is currently owned by institutional investors.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.